REVB
REVELATION BIOSCIENCES, INC.
Key Financials
Net Income
$-8913649
↑ 40.7%
Total Assets
$11.6M
↑ 74.9%
Total Liabilities
$2.7M
↑ 42.2%
Operating Income
$-9070814
↓ 13.7%
Shareholders' Equity
$8.9M
↑ 88.2%
EPS (Diluted)
$-23.95
↑ 72.7%
Cash & Equivalents
$10.7M
↑ 64.6%
Operating Cash Flow
$-8269581.00
↑ 54.9%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| SCHEDULE 13G | 5/15/2026 | View on SEC |
| DEF 14A | 5/11/2026 | View on SEC |
| ARS | 5/11/2026 | View on SEC |
| 8-K | 5/7/2026 | View on SEC |
| 10-Q | 5/7/2026 | View on SEC |
| 4 | 5/1/2026 | View on SEC |
| 4 | 5/1/2026 | View on SEC |
| PRE 14A | 4/30/2026 | View on SEC |
| S-8 | 4/15/2026 | View on SEC |
| 8-K | 3/19/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | REVB |
| Company Name | REVELATION BIOSCIENCES, INC. |
| CIK | 1810560 |
| Sector | Pharmaceutical Preparations |
| Industry | Non-accelerated filer Smaller reporting company |
| Exchange | Nasdaq |
| SIC Code | 2834 |
| SIC Description | Pharmaceutical Preparations |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | DE |
| Phone | 650-800-3717 |